Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 9,115 matching trials from the live ClinicalTrials.gov search.
Filters: Tampa, Florida Clear all
Active, not recruiting Phase 2 Interventional

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399
View directory record Official record
Conditions
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

NCT03531632
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
MGD007 + MGA012
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 31, 2026, 9:43 AM EDT
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

NCT06153693
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
87
States / cities
Alexander City, Alabama • Birmingham, Alabama • Foley, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Terminated Phase 3 Interventional Results available

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319
View directory record Official record
Conditions
Steroid-Refractory Acute Graft Versus Host Disease
Interventions
T-Guard
Drug
Lead sponsor
Xenikos
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

NCT04173507
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Avelumab, Talazoparib, Talazoparib Tosylate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
325
States / cities
Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 31, 2026, 9:43 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
59
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Development and Assessment of a Spanish-Language Hearing Loss Toolkit for Self-Management

NCT04534387
View directory record Official record
Conditions
Hearing Loss
Interventions
Spanish-Language Hearing Loss Toolkit for Self-Management, American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts
Other
Lead sponsor
University of South Florida
Other
Eligibility
50 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 31, 2026, 9:43 AM EDT
Withdrawn Phase 2 Interventional

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

NCT07196306
View directory record Official record
Conditions
COVID, COVID-19, Corona Virus Infection
Interventions
Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 9:43 AM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 3 Interventional

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 31, 2026, 9:43 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

NCT07047716
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis
Interventions
Lenacapavir Injection, Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 1Phase 2 Interventional

Procarbazine in Treating Patients With Recurrent Brain Tumor

NCT00004004
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
procarbazine hydrochloride
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 31, 2026, 9:43 AM EDT
Not listed Not applicable Interventional

Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis

NCT04024033
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
pine cone extract, placebo
Dietary Supplement · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 31, 2026, 9:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Lenalidomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
44
States / cities
Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

NCT01060878
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 31, 2026, 9:43 AM EDT
Completed No phase listed Observational

RNS® System Epilepsy Post-Approval Study

NCT02403843
View directory record Official record
Conditions
Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

NCT07871214
View directory record Official record
Conditions
Early-Stage Non-Small Cell Lung Cancer
Interventions
Pumitamig, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection

NCT00917852
View directory record Official record
Conditions
Thoracic Injuries
Interventions
Gore Conformable TAG Thoracic Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 3 Interventional

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

NCT01052558
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Inject (GTS400), Cataract Surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 31, 2026, 9:43 AM EDT
Completed No phase listed Observational

Gilead Sustained Virologic Response (SVR) Registry

NCT01457755
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
6,625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
162
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

NCT00318643
View directory record Official record
Conditions
Bladder Cancer
Interventions
Mitomycin C, Chemophase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • La Mesa, California • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 31, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of S-3304 in Patients With Solid Tumors

NCT00033215
View directory record Official record
Conditions
Solid Tumors
Interventions
S-3304
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
4
States / cities
Denver, Colorado • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 31, 2026, 9:43 AM EDT